je.st
news
Home
› Oncolytics Biotech submits Orphan Drug Designation for high grade gliomas in pediatric patients
Oncolytics Biotech submits Orphan Drug Designation for high grade gliomas in pediatric patients
2015-02-09 15:30:43| Biotech - Topix.net
Oncolytics Biotech Inc. today announced that it has submitted an application for Orphan Drug Designation to the U.S. Food and Drug Administration for REOLYSIN for the treatment of high grade gliomas in pediatric patients. Oncolytics has conducted three previous clinical studies in brain cancers including gliomas, and has found that REOLYSIN can infect a variety of brain tumors when delivered intravenously.
Tags: high
drug
grade
patients
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||